Related references
Note: Only part of the references are listed.Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald et al.
LANCET (2014)
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Safety and Effect of Very Low Levels of Low-Density Lipoprotein Cholesterol on Cardiovascular Events
John C. LaRosa et al.
AMERICAN JOURNAL OF CARDIOLOGY (2013)
AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 Trial
Nihar R. Desai et al.
CIRCULATION (2013)
Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
Evan A. Stein et al.
CURRENT ATHEROSCLEROSIS REPORTS (2013)
Cochrane review on 'Statins for the treatment of dementia'
Bernadette McGuinness et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2013)
Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications
Seth S. Martin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics
Rose Q. Do et al.
CURRENT CARDIOLOGY REPORTS (2013)
Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial
Frederick Raal et al.
CIRCULATION (2012)
An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
Liwen Zhang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis
S. Matthijs Boekholdt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients The GAUSS Randomized Trial
David Sullivan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Clinical Lipidology Roundtable Discussion Clinical use of genetic typing in human lipid disorders
W. Virgil Brown et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2012)
Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels Results From 2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1 Studies in Healthy Volunteers and Hypercholesterolemic Subjects on Statins
Clapton S. Dias et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
James M. McKenney et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
Michael J. Koren et al.
LANCET (2012)
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
Robert P. Giugliano et al.
LANCET (2012)
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Evan A. Stein et al.
LANCET (2012)
PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
Marie W. Lindholm et al.
MOLECULAR THERAPY (2012)
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
Evan A. Stein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Eli M. Roth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Statin Therapy and the Risk of Intracerebral Hemorrhage A Meta-Analysis of 31 Randomized Controlled Trials
James S. McKinney et al.
STROKE (2012)
Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
Anna Roubtsova et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Clinical aspects of PCSK9
Bertrand Cariou et al.
ATHEROSCLEROSIS (2011)
A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk
Allan D. Sniderman et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2011)
Sources of Variability in Measurements of Cardiac Troponin T in a Community-Based Sample: The Atherosclerosis Risk in Communities Study
Sunil K. Agarwal et al.
CLINICAL CHEMISTRY (2011)
Statins and the risk of new-onset diabetes: a review of recent evidence
David Preiss et al.
CURRENT OPINION IN LIPIDOLOGY (2011)
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy A Meta-analysis
David Preiss et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
Yan G. Ni et al.
JOURNAL OF LIPID RESEARCH (2011)
Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin
Judith Hsia et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Pharmacological strategies for lowering LDL cholesterol: statins and beyond
Ariel Brautbar et al.
NATURE REVIEWS CARDIOLOGY (2011)
Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
G. Tibolla et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2011)
Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans
Lena Persson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population
Qin Cui et al.
ATHEROSCLEROSIS (2010)
Friedewald equation underestimates low-density lipoprotein cholesterol at low concentrations in young people with and without Type 1 diabetes
L. Sibal et al.
DIABETIC MEDICINE (2010)
PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities
Majambu Mbikay et al.
FEBS LETTERS (2010)
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
Greg Welder et al.
JOURNAL OF LIPID RESEARCH (2010)
Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia
Hans J. Avis et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
PCSK9 R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease 3 Independent Studies and Meta-Analyses
Marianne Benn et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
Nidhi Gupta et al.
PLOS ONE (2010)
PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia
Bertrand Cariou et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease
Aaron R. Folsom et al.
ATHEROSCLEROSIS (2009)
Longitudinal Association of PCSK9 Sequence Variations With Low-Density Lipoprotein Cholesterol Levels The Coronary Artery Risk Development in Young Adults Study
Chiang-Ching Huang et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2009)
PCSK9 Impedes Hepatitis C Virus Infection In Vitro and Modulates Liver CD81 Expression
Patrick Labonte et al.
HEPATOLOGY (2009)
Mutations and Polymorphisms in the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene in Cholesterol Metabolism and Disease
Marianne Abifadel et al.
HUMAN MUTATION (2009)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo
Robert J. Schmidt et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
Ahmed Zaid et al.
HEPATOLOGY (2008)
Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9
Trine Ranheim et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9
Holly E. Careskey et al.
JOURNAL OF LIPID RESEARCH (2008)
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Serum proprotein convertase subtilisin Kexin type 9 is correlated directly with serum LDL cholesterol
William E. Alborn et al.
CLINICAL CHEMISTRY (2007)
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Amanda J. Hooper et al.
ATHEROSCLEROSIS (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
David Cunningham et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2007)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2007)
A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol
Tommaso Fasano et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Molecular biology of PCSK9: its role in LDL metabolism
Jay D. Horton et al.
TRENDS IN BIOCHEMICAL SCIENCES (2007)
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk
S. E. Humphries et al.
JOURNAL OF MEDICAL GENETICS (2006)
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
Thomas A. Lagace et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Low density lipoprotein cholesterol, statins and cardiovascular events:: a meta-analysis
B. Genser et al.
CLINICAL RESEARCH IN CARDIOLOGY (2006)
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
KE Berge et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing
SE Humphries et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis
SN Chen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia
KN Maxwell et al.
CURRENT OPINION IN LIPIDOLOGY (2005)
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
CP Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
G Dubuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
S Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Vascular viewpoint - Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Law MR, Wald NJ, Rudnicka AR. BMJ 2003; 326: 1407-408.
SS Anand
VASCULAR MEDICINE (2003)
ACC/AHA/NHLBI clinical advisory on the use and safety of statins
RC Pasternak et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
The Friedewald formula underestimates LDL cholesterol at low concentrations
H Scharnagl et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2001)
Share Paper
